{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:23:37Z","timestamp":1791897817184,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type in the world and is associated with an overall poor prognosis. The protein methyltransferase SET and MYND domain-containing 3 (SMYD3), which trimethylates H3K4, activates gene transcription and enhances several oncogenic pathways, including epithelial-mesenchymal transition and cell cycle related pathways, in various cancer types. It was also recently shown that SMYD3 is overexpressed in HPV-negative HNSCC, and represses the expression of type I IFN response genes, contributing to resistance to anti-PD-1 checkpoint blockade in this disease. In this study, we show that SMYD3 depletion using siRNA interference or CRISPR decreases cellular proliferation and clonal capacity, induces cell cycle arrest and decreases the invasive potential of HPV-negative HNSCC cell lines. Accordingly, xenografts of SMYD3 knockout tumors derived from a human HPV-negative HNSCC cell line grew significantly slower compared to control tumors in mice. Genome-wide mapping for SMYD3 and H3K4me3 in HPV-negative HNSCC cells using cleavage under targets and release using nuclease (CUT&amp;RUN) assays identified direct downstream gene targets regulated by SMYD3, including cell cycle- and EMT-promoting genes. This study provides insights into the epigenetic role of SMYD3 as an oncogene in HPV-negative HNSCC and supports SMYD3 as a rational therapeutic target in HPV-negative HNSCC.<\/jats:p>","DOI":"10.1038\/s41598-024-83396-2","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T14:37:38Z","timestamp":1736174258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["SMYD3 drives cell cycle and epithelial-mesenchymal transition pathways through dual gene transcriptional repression and activation in HPV-negative head and neck cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Madhavi","family":"Murali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunghee","family":"Burkitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arfa","family":"Moshiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Luff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baktiar","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Saloura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"83396_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7\u201330 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"83396_CR2","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet 394, 1915\u20131928 (2019).","journal-title":"Lancet"},{"key":"83396_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ccell.2016.01.013","volume":"29","author":"ME Sarris","year":"2016","unstructured":"Sarris, M. E., Moulos, P., Haroniti, A., Giakountis, A. & Talianidis, I. Smyd3 is a transcriptional potentiator of multiple cancer-promoting genes and required for liver and colon cancer development. Cancer Cell. 29, 354\u2013366 (2016).","journal-title":"Cancer Cell."},{"key":"83396_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/ncb1151","volume":"6","author":"R Hamamoto","year":"2004","unstructured":"Hamamoto, R. et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell. Boil. 6, 731\u2013740 (2004).","journal-title":"Nat. Cell. Boil."},{"key":"83396_CR5","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1038\/s41388-019-0766-x","volume":"38","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2. Oncogene 38, 4948\u20134961 (2019).","journal-title":"Oncogene"},{"key":"83396_CR6","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/nar\/gky1221","volume":"47","author":"C Fenizia","year":"2019","unstructured":"Fenizia, C. et al. SMYD3 promotes the epithelial\u2013mesenchymal transition in breast cancer. Nucl. Acid. Res. 47, 1278\u20131293 (2019).","journal-title":"Nucl. Acid. Res."},{"key":"83396_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc3884","volume":"15","author":"R Hamamoto","year":"2015","unstructured":"Hamamoto, R., Saloura, V. & Nakamura, Y. Critical roles of non-histone protein lysine methylation in human tumorigenesis. Nat. Rev. Cancer 15, 110\u2013124 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"83396_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nature13320","volume":"510","author":"PK Mazur","year":"2014","unstructured":"Mazur, P. K. et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature 510, 283\u2013287 (2014).","journal-title":"Nature"},{"key":"83396_CR9","doi-asserted-by":"publisher","first-page":"75023","DOI":"10.18632\/oncotarget.11898","volume":"7","author":"Y Yoshioka","year":"2016","unstructured":"Yoshioka, Y. et al. SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1. Oncotarget 7, 75023 (2016).","journal-title":"Oncotarget"},{"key":"83396_CR10","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/cam4.1099","volume":"6","author":"Y Yoshioka","year":"2017","unstructured":"Yoshioka, Y. et al. Protein lysine methyltransferase SMYD 3 is involved in tumorigenesis through regulation of HER 2 homodimerization. Cancer Med. 6, 1665\u20131672 (2017).","journal-title":"Cancer Med."},{"key":"83396_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-021-01021-9","volume":"13","author":"BJ Bernard","year":"2021","unstructured":"Bernard, B. J., Nigam, N., Burkitt, K. & Saloura, V. SMYD3: A regulator of epigenetic and signaling pathways in cancer. Clin. Epigen. 13, 1\u201319 (2021).","journal-title":"Clin. Epigen."},{"issue":"7","key":"83396_CR12","doi-asserted-by":"publisher","first-page":"112823","DOI":"10.1016\/j.celrep.2023.112823","volume":"42","author":"N Nigam","year":"2023","unstructured":"Nigam, N. et al. SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck. Cell. Rep. 42(7), 112823 (2023).","journal-title":"Cell. Rep."},{"key":"83396_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. https:\/\/doi.org\/10.1126\/scisignal.2004088 (2013).","journal-title":"Sci. Signal."},{"key":"83396_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"83396_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ccell.2020.12.007","volume":"39","author":"C Huang","year":"2021","unstructured":"Huang, C. et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 39, 361\u2013379 (2021).","journal-title":"Cancer Cell."},{"key":"83396_CR16","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","volume":"25","author":"J Kim","year":"2018","unstructured":"Kim, J. et al. Polycomb-and methylation-independent roles of EZH2 as a transcription activator. Cell. Rep. 25, 2808\u20132820 (2018).","journal-title":"Cell. Rep."},{"key":"83396_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022290","volume":"6","author":"KW Foreman","year":"2011","unstructured":"Foreman, K. W. et al. Structural and functional profiling of the human histone methyltransferase SMYD3. PloS. One 6, e22290 (2011).","journal-title":"PloS. One"},{"key":"83396_CR18","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.7150\/jca.29861","volume":"10","author":"Y Jiang","year":"2019","unstructured":"Jiang, Y. et al. Overexpression of SMYD3 in ovarian cancer is associated with ovarian cancer proliferation and apoptosis via methylating H3K4 and H4K20. J. Cancer 10, 4072 (2019).","journal-title":"J. Cancer"},{"key":"83396_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41419-023-05907-9","volume":"14","author":"Y Zeng","year":"2023","unstructured":"Zeng, Y. et al. SMYD3 drives the proliferation in gastric cancer cells via reducing EMP1 expression in an H4K20me3-dependent manner. Cell. Death Dis. 14, 386 (2023).","journal-title":"Cell. Death Dis."},{"key":"83396_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12915-022-01499-6","volume":"20","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. SMYD3 associates with the NuRD (MTA1\/2) complex to regulate transcription and promote proliferation and invasiveness in hepatocellular carcinoma cells. BMC Biol. 20, 294 (2022).","journal-title":"BMC Biol."},{"key":"83396_CR21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell. Biol. 15, 178\u2013196. https:\/\/doi.org\/10.1038\/nrm3758 (2014).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"83396_CR22","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/s41467-020-16066-2","volume":"11","author":"DP Cook","year":"2020","unstructured":"Cook, D. P. & Vanderhyden, B. C. Context specificity of the EMT transcriptional response. Nat. Commun. 11, 2142. https:\/\/doi.org\/10.1038\/s41467-020-16066-2 (2020).","journal-title":"Nat. Commun."},{"key":"83396_CR23","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/jcp.24975","volume":"230","author":"A Peserico","year":"2015","unstructured":"Peserico, A. et al. A SMYD3 small-molecule inhibitor impairing cancer cell growth. J. Cell. Physiol. 230, 2447\u20132460 (2015).","journal-title":"J. Cell. Physiol."},{"key":"83396_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1021\/acsmedchemlett.5b00272","volume":"7","author":"LH Mitchell","year":"2016","unstructured":"Mitchell, L. H. et al. Novel oxindole sulfonamides and sulfamides: EPZ031686, the first orally bioavailable small molecule SMYD3 inhibitor. ACS Med. Chem. Let. 7, 134\u2013138 (2016).","journal-title":"ACS Med. Chem. Let."},{"key":"83396_CR25","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1177\/24725552211019409","volume":"26","author":"S Gradl","year":"2021","unstructured":"Gradl, S. et al. Discovery of the SMYD3 inhibitor BAY-6035 using thermal shift assay (TSA)-based high-throughput screening. SLAS DISCOV.: Adv. Sci. Drug Discov. 26, 947\u2013960 (2021).","journal-title":"SLAS DISCOV.: Adv. Sci. Drug Discov."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83396-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83396-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83396-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T15:08:42Z","timestamp":1736176122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83396-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["83396"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-83396-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"18 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"984"}}